The GluN2 subtype (2A versus 2B) determines biophysical properties and signaling of forebrain NMDA receptors (NMDARs). During development, GluN2A becomes incorporated into previously GluN2B-dominated NMDARs. This "switch" is proposed to be driven by distinct features of GluN2 cytoplasmic C-terminal domains (CTDs), including a unique CaMKII interaction site in GluN2B that drives removal from the synapse. However, these models remain untested in the context of endogenous NMDARs. We show that, although mutating the endogenous GluN2B CaMKII site has secondary effects on GluN2B CTD phosphorylation, the developmental changes in NMDAR composition occur normally and measures of plasticity and synaptogenesis are unaffected. Moreover, the switch proceeds normally in mice that have the GluN2A CTD replaced by that of GluN2B and commences without an observable decline in GluN2B levels but is impaired by GluN2A haploinsufficiency. Thus, GluN2A expression levels, and not GluN2 subtype-specific CTD-driven events, are the overriding factor in the developmental switch in NMDAR composition.
Pubmed ID: 30355491 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Software suite for electrophysiology data acquisition and analysis by Molecular Devices. Used for the control and recording of voltage clamp, current clamp, and patch clamp experiments. The software suite consists of Clampex 11 Software for data acquisition, AxoScope 11 Software for background recording, Clampfit 11 Software for data analysis, and optional Clampfit Advanced Analysis Module for sophisticated and streamlined analysis.
View all literature mentionsSoftware for image processing, analysis, and editing. The software includes features such as touch capabilities, a customizable toolbar, 2D and 3D image merging, and Cloud access and options.
View all literature mentionsMus musculus with name C57BL/6J from IMSR.
View all literature mentionsThis isotype control targets not applicable
View all literature mentionsThis polyclonal secondary targets IgG
View all literature mentionsThis polyclonal targets Immunoglobulins
View all literature mentionsThis polyclonal targets RCJMB04_4h19
View all literature mentionsThis monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb
View all literature mentionsThis polyclonal targets p44/42 MAPK (Erk1/2)
View all literature mentionsThis monoclonal targets CaMKII alpha
View all literature mentionsThis polyclonal targets NMDAR2A
View all literature mentionsThis unknown targets NMDAR2B
View all literature mentionsThis polyclonal targets NMDAR2B (phospho S1480) antibody
View all literature mentionsThis unknown targets NMDAR2B, phospho (Tyr1472)
View all literature mentionsThis polyclonal targets NR2B, phospho (Ser1303)
View all literature mentionsThis unknown targets NMDAR2B, phospho (Tyr1472)
View all literature mentionsThis polyclonal targets NR2B, phospho (Ser1303)
View all literature mentionsThis polyclonal targets NMDAR2B (phospho S1480) antibody
View all literature mentionsThis unknown targets NMDAR2B
View all literature mentionsThis monoclonal targets CaMKII alpha
View all literature mentionsThis monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb
View all literature mentionsThis polyclonal targets NMDAR2A
View all literature mentionsThis polyclonal targets p44/42 MAPK (Erk1/2)
View all literature mentionsThis isotype control targets not applicable
View all literature mentionsThis polyclonal targets Immunoglobulins
View all literature mentionsThis polyclonal secondary targets IgG
View all literature mentionsThis polyclonal targets RCJMB04_4h19
View all literature mentions